Research programme: Humabody VH antibody fragment-based therapeutics - Crescendo Biologics

Drug Profile

Research programme: Humabody VH antibody fragment-based therapeutics - Crescendo Biologics

Alternative Names: CB 001 - Crescendo Biologics; CB 108; CB 201 - Crescendo Biologics; CB 213; CB 307

Latest Information Update: 06 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Crescendo Biologics
  • Class Immunoglobulin fragments
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Psoriasis

Most Recent Events

  • 06 Jun 2018 VH antibody fragment-based therapeutics - Crescendo Biologics is available for licensing as of 06 Jun 2018.
  • 04 Jun 2018 Zai Lab intends to file an IND application for clinical studies of an antibody VH domain therapeutic in Psoriasis in 2019
  • 30 May 2018 Antibody VH domain therapeutic licensed to Zai Lab worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top